Drug Type TCR therapy |
Synonyms Neoantigen Targeted TCR-T |
Target |
Mechanism Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | - | 01 Apr 2022 |
Phase 1/2 | 6 | TCR-T cell | egoaglrhln(fzujgdzcvx) = wedjbpdfzv ytwwkgorcf (gaobqdefmk ) | Positive | 14 Aug 2023 | ||
Phase 1/2 | Neoplasms KRAS G12D Mutation | 1 | Cyclophosphamide+Fludarabine Phosphate+TCR-T | etkmzcwkzn(eagagyusql) = Grade 4 thrombocytopenia and grade 3 anemia occurred and were both attributed to the lymphodepletion regimen. kooxrzxyez (yvjqkhqxav ) View more | Positive | 21 Sep 2022 |